Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1776, Issue 1, 2007, Pages 1-9

  Konstantinopoulos, Panagiotis A ^a,b   Karamouzis, Michalis V ^a,c   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer related anemia; Erythropoietic effect; Erythropoietin; Selective targeting; Tissue protection

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; STAT5 PROTEIN;

ACUTE CORONARY SYNDROME; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; HEAD AND NECK CANCER; HEART INFARCTION; HEMATOCRIT; HUMAN; HYPERTENSION; KIDNEY DISEASE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT FAILURE; VASCULAR DISEASE;

EID: 34548280928     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2007.07.002     Document Type: Note

References (53)

1. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (Maywood) 228 (2003) 1-14
2. Lacombe C., and Mayeux P. The molecular biology of erythropoietin. Nephrol. Dial. Transplant. 14 (1999) 22-28
3. Brines M., and Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 70 (2006) 246-250
4. Ghezzi P., and Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ. 11 (2004) S37-S44
5. Caro J.J., Salas M., Ward A., and Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91 (2001) 2214-2221
6. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., and Vadhan-Raj S. Impact of therapy with epoetin alpha on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. 15 (1997) 1218-1234
7. Demetri G.D., Kris M., Wade J., Degos L., and Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. 16 (1998) 3412-3425
8. Crawford J., Cella D., Cleeland C.S., Cremieux P.Y., Demetri G.D., Sarokhan B.J., Slavin M.B., and Glaspy J.A. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alpha therapy. Cancer 95 (2002) 888-895
9. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoetin alpha on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19 (2001) 2865-2874
10. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., and Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alpha in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19 (2001) 2875-2882
11. Seidenfeld J., Piper M., Flamm C., Hasselblad V., Armitage J.O., Bennett C.L., Gordon M.S., Lichtin A.E., Wade III J.L., Woolf S., and Aronson N. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J. Natl. Cancer Inst. 93 (2001) 1204-1214
12. Dammacco F., Luccarelli G., Prete M., and Silvestris F. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma. Rev. Clin. Exp. Hematol. Suppl. 1 (2002) 32-38
13. Osterborg A., Brandberg Y., Molostova V., Iosava G., Abdulkadyrov K., Hedenus M., and Messinger D. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J. Clin. Oncol. 20 (2002) 2486-2494
14. Witzig T.E., Silberstein P.T., Loprinzi C.L., Sloan J.A., Novotny P.J., Mailliard J.A., Rowland K.M., Alberts S.R., Krook J.E., Levitt R., and Morton R.F. Phase III, randomized, double-blind study of epoetin alpha compared with placebo in anemic patients receiving chemotherapy. J. Clin. Oncol. 23 (2005) 2606-2617
15. Vansteenkiste J., Pirker R., Massuti B., Barata F., Font A., Fiegl M., Siena S., Gateley J., Tomita D., Colowick A.B., and Musil J. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alpha in lung cancer patients receiving chemotherapy. J. Natl. Cancer Inst. 94 (2002) 1211-1220
16. Hedenus M., Adriansson M., San Miguel J., Kramer M.H., Schipperus M.R., Juvonen E., Taylor K., Belch A., Altes A., Martinelli G., Watson D., Matcham J., Rossi G., and Littlewood T.J. Efficacy and safety of darbepoetin alpha in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br. J. Haematol. 122 (2003) 394-403
17. Glaspy J., Vadhan-Raj S., Patel R., Bosserman L., Hu E., Lloyd R.E., Boccia R.V., Tomita D., and Rossi G. Randomized comparison of every-2-week darbepoetin alpha and weekly epoetin alpha for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J. Clin. Oncol. 24 (2006) 2290-2297
18. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., Makhson A., Roth A., Dodwell D., Baselga J., Biakhov M., Valuckas K., Voznyi E., Liu X., and Vercammen E. Maintaining normal hemoglobin levels with epoetin alpha in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23 (2005) 5960-5972
19. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., Mose S., Beer K.T., Burger U., Dougherty C., and Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
20. Henke M., Mattern D., Pepe M., Bezay C., Weissenberger C., Werner M., and Pajonk F. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J. Clin. Oncol. 24 (2006) 4708-4713
21. Lai S.Y., and Grandis J.R. Understanding the presence and function of erythropoietin receptors on cancer cells. J. Clin. Oncol. 24 (2006) 4675-4676
22. Elliott S., Busse L., Bass M.B., Lu H., Sarosi I., Sinclair A.M., Spahr C., Um M., Van G., and Begley C.G. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107 (2006) 1892-1895
23. Danish Head and Neck Cancer Group, Interim analysis of DAHANCA 10, 2006, 12, 1, Available at http://frejacms.au.dk/dahanca/get_media_file.php?mediaid=125. Accessed May 12, 2007.
24. U.S. Food and Drug Administration, http://www.fda.gov/medwatch/safety/2007/safety07.htm#Aranesp, Accessed May 12, 2007.
25. Wright J.R., Ung Y.C., Julian J.A., Pritchard K.I., Whelan T.J., Smith C., Szechtman B., Roa W., Mulroy L., Rudinskas L., Gagnon B., Okawara G.S., and Levine M.N. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 25 (2007) 1027-1032
26. F. Hoffmann-La Roche Limited. Recruitment Temporarily Suspended Into C.E.R.A. Phase II Oncology Trial, Roche Media News. 2007, 2, 23, Available at http://www.roche.com/med-cor-2007-02-23c. Accessed May 12, 2007.
27. Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarzer G., Sandercock J., Trelle S., Weingart O., Bayliss S., Djulbegovic B., Bennett C.L., Langensiepen S., Hyde C., and Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 98 (2006) 708-714
28. U.S. Food and Drug Administration, http://www.fda.gov/cder/drug/infopage/RHE/default.htm, Accessed May 12, 2007.
29. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Ruther E., Kochen M., Gefeller O., Gleiter C., Wessel T.C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., and Siren A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8 (2002) 495-505
30. Lipsic E., Schoemaker R.G., van der Meer P., Voors A.A., van Veldhuisen D.J., and van Gilst W.H. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J. Am. Coll. Cardiol. 48 (2006) 2161-2167
31. Boogaerts M. Pleiotropic effects of erythropoietin in neuronal and vascular systems. Curr. Med. Res. Opin. 22 Suppl. 4 (2006) 15-22
32. Lipsic E., van der Meer P., Voors A.A., Westenbrink B.D., van den Heuvel A.F., de Boer H.C., van Zonneveld A.J., Schoemaker R.G., van Gilst W.H., Zijlstra F., and van Veldhuisen D.J. A single bolus of a long-acting erythropoietin analogue darbepoetin alpha in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 20 (2006) 135-141
33. Mix T.C., Brenner R.M., Cooper M.E., de Zeeuw D., Ivanovich P., Levey A.S., McGill J.B., McMurray J.J., Parfrey P.S., Parving H.H., Pereira B.J., Remuzzi G., Singh A.K., Solomon S.D., Stehman-Breen C., Toto R.D., and Pfeffer M.A. Rationale-trial to reduce cardiovascular events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am. Heart J. 149 (2005) 408-413
34. Gouva C., Nikolopoulos P., Ioannidis J.P., and Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 66 (2004) 753-760
35. Bahlmann F.H., Song R., Boehm S.M., Mengel M., von Wasielewski R., Lindschau C., Kirsch T., de Groot K., Laudeley R., Niemczyk E., Guler F., Menne J., Haller H., and Fliser D. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110 (2004) 1006-1012
36. Chatterjee P.K. Pleiotropic renal actions of erythropoietin. Lancet 365 (2005) 1890-1892
37. Fisher J.W. A quest for erythropoietin over nine decades. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 1-20
38. Livnah O., Stura E.A., Middleton S.A., Johnson D.L., Jolliffe L.K., and Wilson I.A. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283 (1999) 987-990
39. Rossert J., and Eckardt K.U. Erythropoietin receptors: their role beyond erythropoiesis. Nephrol. Dial. Transplant. 20 (2005) 1025-1028
40. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev., Neurosci. 6 (2005) 484-494
41. Masuda S., Nagao M., Takahata K., Konishi Y., Gallyas Jr. F., Tabira T., and Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J. Biol. Chem. 268 (1993) 11208-11216
42. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.W., Smart J., Su-Rick C.J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., and Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14907-14912
43. Hardee M.E., Arcasoy M.O., Blackwell K.L., Kirkpatrick J.P., and Dewhirst M.W. Erythropoietin biology in cancer. Clin. Cancer Res. 12 (2006) 332-339
44. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., Nakai Y., Isaacs W.B., and Nelson W.G. Inflammation in prostate carcinogenesis. Nat. Rev., Cancer 7 (2007) 256-269
45. Pries R., Nitsch S., and Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Rev. Anticancer Ther. 6 (2006) 1195-1203
46. 2-regulated gene expression. FASEB J. 16 (2002) 1151-1162
47. Minchenko A., Leshchinsky I., Opentanova I., Sang N., Srinivas V., Armstead V., and Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J. Biol. Chem. 277 (2002) 6183-6187
48. Grodberg J., Davis K.L., and Sytkowski A.J. Functional and structural role of arginine 103 in human erythropoietin. Arch. Biochem. Biophys. 333 (1996) 427-431
49. Grodberg J., Davis K.L., and Sytkowski A.J. Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. Eur. J. Biochem. 218 (1993) 597-601
50. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.W., Coleman T., Cerami A., and Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
51. Egrie J.C., and Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant. 16 Suppl. 3 (2001) 3-13
52. Egrie J.C., Dwyer E., Browne J.K., Hitz A., and Lykos M.A. Darbepoetin alpha has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31 (2003) 290-299
53. Erbayraktar S., Grasso G., Sfacteria A., Xie Q.W., Coleman T., Kreilgaard M., Torup L., Sager T., Erbayraktar Z., Gokmen N., Yilmaz O., Ghezzi P., Villa P., Fratelli M., Casagrande S., Leist M., Helboe L., Gerwein J., Christensen S., Geist M.A., Pedersen L.O., Cerami-Hand C., Wuerth J.P., Cerami A., and Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6741-6746